Access to Affordable MedicinesAddiction, Depression, Psychosis, SchizophreniaBusinessDrug PoliticsHealthcare Politics
Psychedelic therapies?
Lancet May 19 2019 Psychedelic therapy
Posts in category Drug Politics
The Case for Rational Drug Policies
Access to Affordable MedicinesAddiction, Depression, Psychosis, SchizophreniaDrug PoliticsHealthcare Politics
Canada’s expanding cannabis market sparks worries
Lancet Jan 12 2019 Canada’s expanding cannabis market
Addiction, Depression, Psychosis, SchizophreniaDiseases of NeglectDrug PoliticsHealthcare PoliticsMedically-Induced Opioid Addiction
Opioid Advertising Worries Continue
CMAJ June 11 2018 Opioid Advertising Worries Remain
Canada’s federal prisons introduce safe needle solutions
Lancet May 26 2018 Canada Reveals Prison Needle Program
New Drugs for Psychosis & Schizophrenia
The Lancet May 5 2018 FDA Pimavanserin review
Addiction, Depression, Psychosis, SchizophreniaCanadian Science PolicyDrug PoliticsHealthcare Politics
Urgent call for cannabis health research solutions
With the deadline for legalization of nonmedical marijuana approaching, scientists studying the health impacts of cannabis are calling on the federal government to implement a comprehensive research program. “Considerably more …
Access to Affordable MedicinesAddiction, Depression, Psychosis, SchizophreniaDrug PoliticsHealthcare PoliticsHealthcare Privatization: A Global Business Campaign
Canada considers fairer pharma prices
Spending by Canadian governments on patented drugs costing more than $10 000 per patient annually increased 60% in 2016 . Spending on brand-name pharmaceuticals as a whole rose 18%.